AccuraSee intraocular pseudophakic contact lens investigated in AMD

Key Takeaways

  • OnPoint Vision is developing an implanted lens to improve vision for patients with age-related macular degeneration (AMD) who have previously undergone cataract surgery.
  • OnPoint has been given FDA approval to start a phase 1 trial of the new lens, which serves as a near magnifier for central vision while keeping the peripheral area neutral.

In a Healio Video Perspective from Eyecelerator@ASCRS (American Society of Cataract and Refractive Surgery meeting), Kevin J. Cady, the founder, president, and CEO of OnPoint Vision, provided an update on the AccuraSee intraocular pseudophakic contact lens. The idea behind the lens is to improve vision in patients who have already undergone cataract surgery by providing a second implanted lens that securely couples to the existing intraocular lens. (Intraocular lenses are used to replace the cloudy lens that is removed during cataract surgery). The first-generation model addresses patients with age-related macular degeneration (AMD) by serving as a near magnifier for central vision while keeping the peripheral area neutral. The new lens has gone through two early feasibility studies, and the company has been given approval by the FDA to start a phase 1 trial.

“The outcomes are looking promising,” Cady said. “We are gaining five to six lines of vision for patients, essentially, you could categorize as going blind. Patients are now able to achieve somewhat functional vision for the first time in a long time with the new lens implant.”

For more information on this trial, visit https://onpoint-vision.com/clinical-studies/ or contact OnPoint at 949-842-9954 or nedwards@onpoint-vision.com

Source: Kevin J. Cady and Sara Kellner, Healio Ocular Surgery News, April 24, 2024; see source video